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http://dxBackground: Allosensitization in potential orthotopic heart transplant recipients is evaluated with the panel
reactive antibody assay. Sensitized patients have prolonged wait times and increased waitlist and post-
transplant mortality. Although low panel reactive antibody activity at the time of orthotopic heart transplantation
is associated with improved outcomes, literature regarding the survival benefit of a panel reactive antibody
reduction in the sensitized orthotopic heart transplant recipient remains limited.
Methods: Adult orthotopic heart transplant recipients listed in the United Network for Organ Sharing database
(October 1, 1987, to June 29, 2004) were stratified by peak panel reactive antibody activity and whether
a substantial decline from peak to most recent panel reactive antibody activity occurred before transplant. Pro-
pensity matching adjusted for differences in recipient and donor characteristics. Graft survival was assessed with
Kaplan–Meier analysis. Cox proportional hazards regression determined predictors of graft survival.
Results: Pretransplant characteristics differed between sensitized patients who had a substantial decline in panel
reactive antibody activity and those who did not. Propensity matching compensated for these differences.
Kaplan–Meier survival analysis of matched groups showed that the median graft survival was 120 months in
patients with a significant panel reactive antibody reduction and 103 months in patients with a trivial reduction
(P ¼ .007, log-rank). In Cox proportional hazards modeling, a significant reduction in panel reactive antibody
activity had an independent protective effect on graft survival (hazard ratio, 0.88; confidence interval, 0.80-0.96;
P ¼ .006).
Conclusions: Sensitized patients who had a substantial reduction in panel reactive antibody activity had an
associated decline in the incidence of graft failure comparedwith thosewithout a panel reactive antibody activity
reduction. These results support efforts to reduce panel reactive antibody activity before orthotopic heart trans-
plantation in patients with high panel reactive antibody activity. (J Thorac Cardiovasc Surg 2013;145:555-65)Allosensitization is a condition in which recipient serum an-
tibodies react against donor antigens.1 It can be directly as-
sessed by the donor-specific crossmatch, wherein recipient
serum is mixed with antigen derived from donor leukocytes
to determine cross-reactivity, a so-called ‘‘cell-based’’
approach.2 As initially shown in kidney transplantation,
a positive donor-specific crossmatch is associated with
decreased graft survival after orthotopic heart transplanta-
tion (OHT).3,4 Although retrospective crossmatches are
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Xthe need for a source of both donor leukocytes and
recipient serum to perform the assay, the cold ischemic
time constraint associated with OHT, and the low
sensitivity and specificity of the assay make prospectively
crossmatching all OHT recipients a near impossibility.5,6
Instead, allosensitization is prospectively assessed by the
panel reactive antibody (PRA) test, wherein an intended
recipient’s serum is exposed to several different human
leukocyte antigen (HLA)–typed lymphocytes representing
theoretic donors (again, a cell-based approach) to assess
HLA cross-reactivity; the percentage of theoretic donor cells
that react is used as a surrogate for sensitization.1 In OHT re-
cipients, as was first shown in kidney recipients, elevated
PRA activity is associated with decreased graft survival;
this association is independent of the crossmatch result.4,7-9
Despite numerous modifications—including wash steps
to remove anti-complimentary factors, increased incubation
times, and the addition of anti-human immunoglobulin to
facilitate binding of low-avidity, low-titer, and noncomple-
ment fixing antibodies—cell-based approaches remain lim-
ited by their relatively poor sensitivity and specificity, the
arbitrary composition of target cell panels, issues related
to cell viability, and the restriction of cell-based tests to de-
tecting class I antibodies only.10-12 The recent introductionrdiovascular Surgery c Volume 145, Number 2 555
Abbreviations and Acronyms
BMI ¼ body mass index
CI ¼ confidence interval
ECMO ¼ extracorporeal membrane oxygenation
EPY ¼ events per patient year
HLA ¼ human leukocyte antigen
HR ¼ hazard ratio
MHC ¼ major histocompatibility complex
OHT ¼ orthotopic heart transplantation
PRA ¼ panel reactive antibody
UNOS ¼ United Network for Organ Sharing
VAD ¼ ventricular assist device
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Xof solid-phase assays, in particular single-antigen HLA
beads (HLA class I or II antigens produced by recombinant
DNA technologies and attached to inert microparticles), has
addressed many of the limitations of cell-based ap-
proaches.6,12 These highly sensitive and specific assays
have fostered the development of the virtual crossmatch
and calculated PRA tests, in which recipient serum anti-
HLA specificities derived from solid-phase assays are com-
pared with the HLA antigen profile of a specific donor
(virtual crossmatch) orHLA antigen frequencies in a sample
donor pool (calculated PRA).13,14
Regardless of the assay used, elevated PRA activity had
dire implications for potential recipients because it limits
the acceptable donor pool and prolongs waitlist times,
thereby increasing the incidence of waitlist mortality in
these patients.15 Efforts to achieve a donor–recipient match
in allosensitized patients involve closely monitoring PRA
activity, strictly avoiding further exposure to foreign human
antigens, and adopting an assortment of therapies aimed at
reducing allosensitization, including plasmapheresis, intra-
venous immunoglobulin, rituximab, and bortezomib.1 Sev-
eral institutional studies have shown that implementing
these allosensitization-reduction strategies reduces PRA
activity and waitlist durations and produces graft survivals
similar to those of nonsensitized patients.1,16-19 However,
there remains a dearth of literature regarding long-term
graft survival in previously allosensitized patients whose
level of allosensitization is significantly improved before
transplant. To address this question, we reviewed the United
Network for Organ Sharing (UNOS) database to assess
graft survival in patients with significantly reduced allosen-
sitization as indicated by pretransplant PRA activity.
MATERIALS AND METHODS
Data Collection and Study Cohort
We performed a retrospective review of deidentified data from the
UNOS thoracic registry. Our institutional research ethics board waived
the requirement for informed consent because no patient or center identi-
fiers were included in the analysis. A total of 52,204 usable records of
patients who underwent OHT between October 1, 1987, and December556 The Journal of Thoracic and Cardiovascular Surg31, 2011, were identified. Before June 30, 2004, the UNOS registry did
not record PRA activity for HLA class II antigens because it was not as-
sessed by most assays in clinical use at that time. The wide adoption of
solid-phase assays by transplant centers occurred after June 30, 2004, mak-
ing this early population more homogenous with respect to PRA assay.1
Moreover, as the number of patients bridged to transplant with a ventricular
assist device (VAD) has increased, the effect of mechanical circulatory sup-
port on PRA activity has been well documented.20,21 Given our aim to
address long-term graft survival and to avoid confounding by the various
PRA assays, separate HLA class I/II PRA activity measurements, and
the effect of VADs on PRA activity, we limited our study to the 27,102 adult
patients who underwent transplantation before June 30, 2004 (before the
registry began to distinguish between PRA HLA classes), whose peak
andmost recent PRA activity were documented (class I major histocompat-
ibility complex [MHC] only). Specific focus was devoted to patients with
a peak PRA of 0% (n ¼ 18,163) representing a nonsensitized control,
patients with a peak PRA of 20% or greater and a trivial (<5%) absolute
reduction in PRA activity (n¼ 1016), and patients with a peak PRA of 20%
or greater and a substantial (20%) absolute reduction in PRA activity
(n ¼ 1244). Of note, many patients (n ¼ 6679) had a modest PRA activity
(<20%) or a moderate reduction in PRA activity (5% and<20%); these
patients were included in our Cox proportional hazards analysis but were
omitted from our unmatched and matched Kaplan–Meier survival analyses
to allow for a direct comparison of PRA-reduction nonresponders and
responders. Patient follow-up data were available to March 31, 2012.Statistical Analysis
Demographics and clinical status were obtained for all patients at the
time of transplantation. Variables with missing values were imputed to
avoid listwise deletion in our analysis. Multiple imputation was performed
(n¼ 20)with aMarkov chainMonte Carlomethod that assumed amultivar-
iate normal distribution for our data; the complete sets of observed values
were used as covariates for prediction purposes. Analysis of variance was
used to compare demographics and clinical status at the time of transplant
among patients with a peak PRA activity of 0% (nonsensitized control),
patients with a peak PRA activity of 20% or greater who had a trivial
(<5%) absolute reduction in PRA activity, and patients with a peak PRA
activity of 20% or greater who had a significant (20%) absolute reduc-
tion in PRA activity.
The primary outcomemeasurewas graft survival (a composite end point
of death and graft failure). The Kaplan–Meier method was used to examine
graft survival over time, and the log-rank test was used to examine differ-
ences in graft survival curves. Censoring occurred for patients who were
alive and had not undergone a repeat OHT at the last time point examined
(administratively censored). Unadjusted survival analysis was assessed for
each of the 3 groups described previously (peak PRA 0%, trivial PRA
reduction, substantial PRA reduction).
To better control for selection bias, we subsequently carried out propen-
sity score matching. A multivariable logistic regression model was used to
compute propensity scores for patients with a peak PRA of 20% or greater
who had a trivial reduction (<5%) or a significant reduction (20%) in
PRA activity in each of our 20 imputed datasets. These 20 propensity scores
were then averaged and applied to our original data set. We next carried out
a 1:1 propensity score matching analysis with a greedy matching algorithm
(nearest neighbor matching within a caliper width of 1/4th of the standard
deviation of the logit of the propensity score); patients without a match
were excluded from the matched sample. After propensity matching, we
compared matched patients with a trivial PRA reduction with those who
had a significant reduction by using 2-sample t tests for continuous variables
and the chi-square or Fisher exact test for categoric variables.Kaplan–Meier
survival analysis assessed graft survival for the propensity-matched cohort.
Univariate andmultivariable Cox proportional hazards regression analy-
seswereused to assess the effect of listing characteristics ongraft survival.A
multivariablemodelwas constructed fromvariables thatwere both plausibleery c February 2013
Schaffer et al Cardiothoracic Transplantationfor and predictive of mortality in our exploratory univariate analysis (P 
.20). Forward and backward stepwise selection were used to help ensure
that the final model would be optimal. The final model included the follow-
ing variables: age more than 60 years, African-American race, college edu-
cation, private insurance, diagnosis of idiopathic dilated cardiomyopathy,
diagnosis of congenital heart disease, undergoing redo heart transplantation,
year of transplant, body mass index (BMI) 35 kg/m2 or greater, ventilator
dependence, extracorporeal membrane oxygenation (ECMO) support, cre-
atinine clearance less than 50mL/min, dialysis requirement, diabetes, serum
bilirubin level 2 mg/dL or greater, organ ischemic time (hours), donor age,
gender match between organ and recipient, peak PRA activity, and whether
a substantial reduction in PRA activity was documented.
Means are presented with standard deviations, and hazard ratios (HRs)
are presented with 95% confidence intervals (CIs). Analyses were conduct-
ed with STATA software (v 11SE, StataCorp LP, College Station, Tex).RESULTS
We identified 52,204 usable patient records in the UNOS
thoracic registry of patients who underwent OHT between
October 1, 1987, and December 31, 2011. Of these patients,
45,592 were adults (aged 18 years) at the time of trans-
plant. Our analysis was limited to the 31,551 adult patients
who underwent OHT before June 30, 2004 (when the
UNOS thoracic registry began to distinguish between
PRA major histocompatibility classes); of these, 4449 pa-
tients were excluded because their peak or most recent
PRA values were not documented. Thus, a total of 27,102
patients were included in this study. The trends in peak
and most recent PRA activity over time (Figure 1) are nota-
ble for an increase in PRA values over the duration of the
study period.Baseline Characteristics at the Time of Transplant
Forty-five variables detailing patient characteristics and
operation-specific data are described in Table 1, stratified
by whether the peak PRA activity was 0% (n ¼ 18,163),
the peak PRA activity was 20% or higher but only a trivial
(<5%) absolute reduction in PRA activity was achievedFIGURE 1. Bar graph of trends in PRA activity (both peak and most re-
cent) at the time of transplant, stratified by year of transplant. Error bars
represent 95% CIs. PRA, Panel reactive antibody.
The Journal of Thoracic and Ca(n ¼ 1016), or the peak PRA activity was 20% or higher
and a substantial absolute reduction in PRA activity
(20%) was observed (n ¼ 1244). The amount of missing
data was significant (<90% complete) for several variables,
including level of education, insurance status, New York
Heart Association functional status, creatinine clearance,
dialysis requirement, diabetes, serum bilirubin, and hemo-
dynamic parameters (ie, cardiac index, pulmonary artery
pressures, and pulmonary capillary wedge pressures). As
described in the ‘‘Materials and Methods,’’ multiple impu-
tation was used to account for missing data. Small but sta-
tistically significant differences were noted in several
pretransplant and operative variables, including age at
transplant, gender, diagnosis, redo OHT, BMI, listing status,
New York Heart Association functional status, inotrope re-
quirement, intra-aortic balloon pump requirement, VAD
use, creatinine clearance, bicaval technique, organ ischemic
time, and distance of organ transport (Table 1).Cox Proportional Hazards Analysis of Graft Survival
Univariate and multivariable Cox proportional hazards
analyses were used to identify predictors of graft survival
(Table 2). A substantial reduction in PRA activity was not
a predictor of graft survival on univariate analysis (HR,
1.05; 95% CI, 0.97-1.13; P ¼ .22). We suspected that hav-
ing a PRA reduction was necessarily confounded by having
a high peak PRA activity, and we thus included peak PRA
activity in our multivariable analysis. Once multivariable
analysis accounted for a patient’s peak PRA activity,
achieving a substantial reduction in PRA activity signifi-
cantly protected against graft dysfunction (HR, 0.88; CI,
0.80-0.96; P ¼ .006), whereas the peak PRA activity re-
mained an independent predictor of graft dysfunction or
death (HR, 1.003; CI, 1.002-1.004; P< .001). Of note,
when all 3 measures of PRA activity (peak PRA activity,
most recent PRA activity, and substantial PRA activity re-
duction) were included in our multivariable analysis, most
recent PRA activity lost statistical significance, whereas
peak PRA activity and substantial PRA activity reduction
remained statistically significant (Table 2).T
XGraft Survival Analysis: Unadjusted
The mean follow-up time from the time of transplant was
3060  2026 days in patients who had a trivial reduction in
PRA activity and 2987  1973 days in patients who had
a substantial PRA reduction. Figure 2 shows an unadjusted
Kaplan–Meier estimate of graft survival from time of trans-
plant, stratified by whether the patient had an elevated peak
PRA activity and whether a trivial or significant PRA reduc-
tion was achieved; median graft survival was 131 months in
patients with a peak PRA activity of 0%, 102 months in pa-
tients with a peak PRA activity of 20% or greater who only
had a trivial PRA reduction, and 121months in patients withrdiovascular Surgery c Volume 145, Number 2 557
TABLE 1. Baseline characteristics at time of heart transplant, shown for the entire cohort, stratified by peak panel reactive antibody and panel
reactive antibody reduction, and for the propensity-matched patients
Overall cohort
Unadjusted analysis, stratified by peak and
most recent PRA activity
Nonmissing data
(n ¼ 27,102)
Overall cohort
(n ¼ 27,102)
Peak PRA ¼ 0%, no
reduction in PRA
(n ¼ 18,163)
Peak PRA  20%,
trivial reduction in
PRA (<5%) (n ¼ 1016)
Baseline characteristics
Age at transplant 27,102 (100%) 51.5  11.2 51.8  11.1 50.3  11.9
Age>60 y at transplant 27,102 (100%) 5765 (21.3%) 4000 (22.0%) 204 (20.1%)
Gender (male) 27,102 (100%) 21,103 (77.9%) 14,414 (79.4%) 622 (61.2%)
Race (Caucasian) 27,102 (100%) 22,134 (81.7%) 14,889 (82.0%) 796 (78.4%)
Race (African-American) 27,102 (100%) 3106 (11.5%) 2013 (11.1%) 147 (14.5%)
Race (Hispanic) 27,102 (100%) 1357 (5.0%) 910 (5.0%) 54 (5.3%)
Education (college) 12,855 (47.4%) 6065 (47.2%) 4259 (47.5%) 209 (43.5%)
Insurance (private) 18,135 (66.9%) 11,223 (61.9%) 7643 (62.3%) 425 (61.2%)
Ischemic dilated cardiomyopathy 27,013 (99.7%) 13,425 (49.7%) 9118 (50.3%) 460 (45.5%)
Idiopathic dilated cardiomyopathy 27,013 (99.7%) 9408 (34.8%) 6322 (34.9%) 350 (34.6%)
Valvular heart disease 27,013 (99.7%) 822 (3.0%) 510 (2.8%) 40 (4.0%)
Heart retransplant 27,013 (99.7%) 679 (2.5%) 344 (1.9%) 46 (4.6%)
Congenital heart disease 27,013 (99.7%) 501 (1.9%) 332 (1.8%) 31 (3.0%)
Year of transplant 27,102 (100%) 1996 IQR, 1993-2000 1996 IQR, 1993-2000 1997 IQR, 1993-2000
BMI (kg/m2) 26,750 (98.7%) 25.7  5.0 25.7  5.1 25.1  4.7
BMI  35 kg/m2 26,750 (98.7%) 803 (3.0%) 520 (2.9%) 23 (2.3%)
Status 1A 26,360 (97.3%) 13,400 (50.8%) 8825 (49.8%) 603 (61.6%)
Status 1A or 1B 26,360 (97.3%) 16,972 (64.4%) 11,215 (63.3%) 743 (75.9%)
NYHA class IV 11,666 (44.3%) 610 (5.2%) 416 (5.2%) 21 (5.8%)
NYHA class III-IV 11,666 (44.3%) 7541 (65.6%) 5266 (65.2%) 232 (64.3%)
Life support
Ventilator, n (%) 27,102 (100%) 802 (3.0%) 536 (3.0%) 44 (4.3%)
Inotropes, n (%) 27,102 (100%) 11,142 (41.1%) 7813 (43.0%) 405 (39.9%)
Intra-aortic balloon pump, n (%) 27,102 (100%) 1510 (5.6%) 1025 (5.6%) 61 (6.0%)
ECMO, n (%) 27,102 (100%) 44 (0.2%) 33 (0.2%) 2 (0.2%)
VAD, n (%) 27,102 (100%) 140 (0.5%) 69 (0.4%) 7 (0.7%)
Renal function, diabetes, bilirubin
Creatinine clearance 18,769 (69.3%) 77.7  37.9 77.5  37.5 76.3  34.4
Creatinine clearance<50 mL/min 18,769 (69.3%) 3486 (18.6%) 2365 (18.4%) 145 (20.9%)
Dialysis, n (%) 18,903 (69.7%) 586 (3.1%) 315 (2.5%) 37 (5.2%)
Diabetes, n (%) 17,294 (63.8%) 3170 (18.3%) 2172 (18.5%) 108 (16.2%)
Serum bilirubin (mg/dL) 17,237 (63.6%) 1.37  3.49 1.32  3.07 1.29  3.39
Serum bilirubin 2 mg/dL) 17,237 (63.6%) 1974 (11.5%) 1325 (11.2%) 82 (12.6%)
Hemodynamic parameters
Cardiac index (L/min/m2) 17,758 (65.5%) 2.27  0.75 2.27  0.74 2.24  0.77
Systolic pulmonary artery pressure (mm Hg) 18,272 (67.4%) 44.4  15.2 44.4  15.3 45.6  14.8
Mean pulmonary artery pressure (mm Hg) 17,853 (65.9%) 30.2  10.8 30.1  10.9 31.3  10.8
Pulmonary capillary wedge pressure (mm Hg) 18,011 (66.5%) 20.5  9.1 20.5  9.1 21.4  9.3
Donor/operative characteristics
Bicaval 27,003 (99.6%) 3601 (13.3%) 2419 (13.4%) 135 (13.4%)
Organ ischemic time (h) 25,297 (93.3%) 2.86  1.01 2.86  1.01 2.94  1.03
Distance organ transported (miles) 26,117 (96.4%) 127  189 131  191 119  188
Donor age (y) 27,100 (99.9%) 30.4  12.5 30.4  12.5 30.6  12.7
Gender match 27,102 (100%) 18,801 (69.4%) 12,563 (69.2%) 640 (63.0%)
Race match 27,001 (99.6%) 18,261 (67.6%) 12,359 (68.3%) 639 (62.3%)
PRA activity
Substantial (20%) absolute reduction in PRA activity 27,102 (100%) 1244 (4.6%) 0 (0.0%) 0 (0.0%)
Peak PRA activity (%) 27,102 (100%) 6.6  17.8 0  0.0 52.9  26.8
Most recent PRA activity (%) 27,102 (100%) 3.7  13.0 0  0.0 52.7  26.8
P values<.05 are in bold. PRA, Panel reactive antibody; BMI, body mass index; NYHA, New York Heart Association; ECMO, extracorporeal membrane oxygenation; VAD,
ventricular assist device; IQR, interquartile range. *P value based on analysis of variance. yP value based on chi-square or Student t test analysis.
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Unadjusted analysis, stratified by peak and
most recent PRA activity Propensity-matched analysis
Peak PRA  20%,
substantial reduction in
PRA (20%) (n ¼ 1244) P*
Peak PRA  20%,
trivial reduction in
PRA (<5%) (n ¼ 945)
Peak PRA  20%,
substantial reduction in
PRA (20%) (n ¼ 945) Py
50.6  11.5 <.001 50.8  11.4 50.5  11.8 .54
237 (19.1%) .02 194 (20.5%) 190 (20.1%) .82
841 (67.6%) <.001 602 (63.7%) 599 (63.4%) .89
1005 (80.8%) .01 746 (78.9%) 755 (79.9%) .61
167 (13.4%) <.001 133 (14.1%) 124 (13.1%) .55
56 (4.5%) .65 50 (5.3%) 51 (5.4%) .92
264 (44.6%) .10 197 (43.3%) 192 (43.2%) .99
585 (63.9%) .52 408 (61.9%) 421 (61.6%) .92
588 (47.4%) .002 443 (47.1%) 445 (47.3%) .93
387 (31.2%) .03 319 (33.9%) 316 (33.6%) .88
58 (4.7%) <.001 40 (4.3%) 42 (4.5%) .82
88 (7.1%) <.001 45 (4.8%) 45 (4.8%) 1.00
19 (1.5%) .01 17 (1.8%) 19 (2.0%) .74
1997 IQR, 1994-2000 1997 IQR, 1993-2000 1997 IQR, 1994-2000
26.1  5.5 <.001 25.3  4.6 25.4  4.6 .60
49 (4.0%) .04 22 (2.4%) 22 (2.4%) .98
686 (56.7%) <.001 555 (60.7%) 550 (60.2%) .81
916 (75.7%) <.001 692 (75.7%) 690 (75.5%) .91
34 (6.8%) .24 20 (5.7%) 18 (4.8%) .59
316 (63.5%) .70 227 (65.0%) 245 (65.9%) .82
47 (3.8%) .02 40 (4.2%) 38 (4.0%) .82
474 (38.1%) .001 371 (39.3%) 370 (39.2%) .96
58 (4.7%) .29 51 (5.4%) 51 (5.4%) 1.00
2 (0.2%) .98 1 (0.1%) 2 (0.2%) .56
17 (1.4%) <.001 7 (0.7%) 10 (1.1%) .47
77.5  37.8 .72 76.0  34.5 76.2  37.2 .92
202 (22.4%) .004 140 (21.2%) 152 (22.6%) .54
53 (5.7%) <.001 35 (5.2%) 34 (4.8%) .76
152 (17.4%) .27 104 (16.5%) 124 (18.8%) .29
1.29  2.81 .95 1.30  3.47 1.38  3.21 .68
90 (10.8%) .53 76 (12.3%) 71 (11.6%) .70
2.30  0.77 .30 2.26  0.77 2.22  0.72 .37
44.3  14.9 .13 45.5  17.8 45.6  15.2 .88
30.0  10.5 .02 31.2  10.7 31.2  10.8 .91
20.5  9.1 .06 21.2  9.2 21.5  9.2 .59
188 (15.2%) .20 125 (13.3%) 142 (15.1%) .27
2.96  1.06 <.001 2.94  1.04 2.97  1.07 .60
113  170 .002 117  186 118  179 .91
30.5  12.3 .78 30.9  12.7 30.6  12.4 .60
867 (69.7%) <.001 618 (65.4%) 617 (65.3%) .96
821 (66.3%) .001 604 (63.9%) 615 (65.4%) .49
1244 (100%) <.001 0 (0.0%) 945 (100%) <.001
56.1  26.4 <.001 53.4  26.9 53.5  27.1 .88
9.9  16.9 <.001 53.2  26.8 11.6  19.1 <.001
TABLE 1. Continued
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TABLE 2. Multivariable predictors of graft survival according to a Cox proportional hazards regression analysis
Multivariable hazard
ratio (95% CI) P*
Univariate hazard
ratio (95% CI) Py
Baseline characteristics
Age at transplant (y) 1.008 (1.006-1.009) <.001
Age>60 y at transplant 1.20 (1.16-1.25) <.001 1.24 (1.19-1.28) <.001
Gender (male) 1.01 (0.97-1.05) .58
Race (Caucasian) 0.85 (0.82-0.89) <.001
Race (African-American) 1.39 (1.33-1.46) <.001 1.31 (1.25-1.37) <.001
Race (Hispanic) 0.97 (0.90-1.04) .39
College education 0.96 (0.92-0.99) .02 0.92 (0.89-0.96) <.001
Insurance (private) 0.90 (0.87-0.94) <.001 0.86 (0.82-0.89) <.001
Ischemic dilated cardiomyopathy 1.20 (1.16-1.25) <.001 1.19 (1.15-1.22) <.001
Idiopathic dilated cardiomyopathy 0.85 (0.83-0.88) <.001
Valvular heart disease 0.87 (0.79-0.95) .003
Heart retransplant 1.51 (1.37-1.67) <.001 1.41 (1.29-1.56) <.001
Congenital heart disease 1.16 (1.02-1.31) .02 0.95 (0.84-1.08) .20
Year of transplant 0.97 (0.96-0.98) <.001 0.982 (0.978-0.986) <.001
BMI (kg/m2) 1.007 (1.004-1.010) <.001
BMI  35 kg/m2 1.19 (1.09-1.31) <.001 1.15 (1.05-1.26) .004
Status 1A 1.06 (1.03-1.10) <.001
Status 1A or 1B 1.01 (0.98-1.05) .39
NYHA class IV 0.99 (0.89-1.09) .77
NYHA class III-IV 1.01 (0.97-1.05) .50
Life support
Ventilator 1.47 (1.35-1.61) <.001 1.62 (1.49-1.77) <.001
Inotropes 1.00 (0.96-1.03) .79
Intra-aortic balloon pump 1.19 (1.12-1.28) <.001
ECMO 1.60 (1.14-2.25) .007 2.18 (1.56-3.05) <.001
VAD 1.00 (0.77-1.30) .98
Renal function, diabetes, bilirubin
Serum creatinine (mg/dL) 1.026 (1.015-1.036) <.001
Creatinine clearance (mL/min) 0.998 (0.997-0.999) <.001
Creatinine clearance<50 mL/min 1.13 (1.08-1.19) <.001 1.24 (1.19-1.30) <.001
Dialysis 1.19 (1.08-1.32) .001 1.31 (1.18-1.45) <.001
Diabetes 1.15 (1.09-1.21) <.001 1.18 (1.12-1.24) <.001
Serum bilirubin (mg/dL) 1.006 (1.001-1.010) .02
Serum bilirubin 2 mg/dL 1.09 (1.03-1.16) .005 1.11 (1.04-1.18) .001
Hemodynamic parameters
Cardiac index (L/min/m2) 0.98 (0.96-1.01) .15
Systolic pulmonary artery pressure (mm Hg) 1.002 (1.001-1.003) <.001
Mean pulmonary artery pressure (mm Hg) 1.002 (1.000-1.004) .01
Pulmonary capillary wedge pressure (mm Hg) 1.001 (0.999-1.003) .24
Donor/operative characteristics
Bicaval 0.89 (0.84-0.94) <.001
Organ ischemic time 1.05 (1.03-1.06) <.001 1.04 (1.02-1.06) <.001
Distance organ transported 1.000 (1.000-1.001) .08
Donor age 1.010 (1.009-1.011) <.001 1.011 (1.009-1.012) <.001
Gender match 0.95 (0.91-0.98) .001 0.92 (0.89-0.95) <.001
Race match 0.92 (0.89-0.95) <.001
PRA activity
Substantial (20%) absolute reduction in PRA activity 0.88 (0.80-0.96) .006 1.05 (0.97-1.13) .22
Peak PRA activity 1.0032 (1.0022-1.0043) <.001 1.0024 (1.0016-1.0033) <.001
Most recent PRA activity 1.0036 (1.0025-1.0047) <.001
P values<.05 are in bold. CI, Confidence interval; BMI, body mass index; NYHA, New York Heart Association; ECMO, extracorporeal membrane oxygenation; VAD, ventricular
assist device; PRA, panel reactive antibody. *P value based on multivariable Cox proportional hazards analysis. yP value based on univariate Cox proportional hazards analysis.
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FIGURE 2. Unadjusted Kaplan–Meier estimate of graft survival after
heart transplant, stratified by whether the patient had a peak PRA activity
of 0% (ie, no reduction in PRA activity was possible because the peak was
0%) (PK0NR), a peak PRA of 20% or greater but a trivial absolute reduc-
tion (<5%) in PRA activity (PK20TR), or a peak PRA of 20% or greater
and a substantial absolute reduction (20%) in PRA activity (PK20SR).
PRA, Panel reactive antibody.
Schaffer et al Cardiothoracic Transplantation
T
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PRA reduction (P  .01 for all comparisons, log-rank).
Propensity-Matched Analysis of Survival After
Transplantation
Among the patients with elevated PRA activity (20%),
matching 1:1 by propensity score matched 945 patients who
had a trivial reduction in PRA activity with 945 patients
who had a significant reduction. Histograms depicting the
distribution of propensity scores for patients with an ele-
vated PRA activity (20%) who had a trivial or significant
PRA activity reduction are shown for the entire cohort
(Figure 3, A) and the propensity-matched subgroup
(Figure 3, B). Patient and operation-specific characteristics
for the propensity-matched cohort are listed in Table 1.
None of the matched preoperative and operative variables
were statistically different between groups in the matched
cohort, including peak PRA activity. However, the most
recent PRA activity (the dependent variable) was 53.2%
(26.8%) in matched patients with a trivial PRA reduction
and only 11.6% (19.1%) in matched patients with a sig-
nificant PRA reduction (P<.001), indicating that on aver-
age, an absolute reduction in PRA activity of more than
40% was observed in the matched ‘‘significant PRA reduc-
tion’’ cohort. A Kaplan–Meier estimate of graft survival
(Figure 4) showed a median survival of 120 months in pa-
tients with a significant PRA reduction and 103 months in
patients with a trivial PRA reduction (P ¼ .007, log-rank).
Early and Late Graft Survival
The association of a significant PRA reduction with early
and late outcomes is shown in Table 3. The effect of a signifi-
cant PRA reduction was most notable in early (30-day) out-
comes: Patients with a significant PRA reduction had a 50%The Journal of Thoracic and Cadecrease in the incidence of death or graft failure (1.15 events
per patient year [EPY] vs 1.77EPY,whereas the event ratewas
0.80 EPY in nonsensitized patients with a peak PRA of 0%).
As expected, the incidence of death or graft failure declined
substantially over time, stabilizing at an event rate of 0.07
EPYinpatientswith trivially reducedPRAand0.06EPYinpa-
tients with substantially reduced PRA, compared with 0.06
EPY in patients with a peak PRA of 0%.
DISCUSSION
The current study examined graft survival and potential
predictors of graft survival in patients who had a significant
reduction in PRA activity and patients who had a trivial
reduction in PRA activity. We limited our analysis to an ear-
lier cohort (from 1987 to 2004) of heart transplant recipients
to facilitate the assessment of long-term graft survival, to
avoid confounding between the 2 eras of PRA recording
(MHC class nonspecific vs specific), to minimize the effect
of differences in PRA assay (cell-based vs solid-phase), and
to avoid confounding the higher PRA activity noted in VAD
recipients (of whom there were few in the 1987-2004 era)
with graft survival. Cox proportional hazards analysis and
propensity-matched techniques were used to minimize
selection bias. Our findings suggest that achieving a substan-
tial PRA activity reduction is an independent predictor of
graft survival, and that patients who have a substantial
PRA reduction attain 10-year graft survival outcomes
approaching (but not equal to) those of nonsensitized
patients (peak PRA activity of 0%).
Panel Reactive Antibody Activity and Significant
Reduction in Panel Reactive Antibody Activity as
Independent Predictors of Graft Survival
Our findings suggest that higher peak PRA activity is
associated with poorer graft survival in heart transplant
recipients (Table 2). Although previous studies have identi-
fied elevated PRA activity as a predictor of graft dysfunc-
tion in heart transplantation, these studies did not
differentiate between peak and most recent PRA activity,
nor did they include both peak activity and substantial
PRA activity reduction in a multivariable analysis.4,8,9
Thus, our analysis produced a novel finding: Peak PRA
activity and whether a significant PRA reduction was
achieved were independent predictors of graft survival. Of
note, in the multivariate analysis, the most recent PRA
activity did not predict graft survival independently of
peak PRA activity and substantial PRA activity reduction,
suggesting that these 2 variables alone adequately account
for the effect of elevated PRA activity on graft survival.
Other Predictors of Graft Survival
In addition to peak PRAactivity and a substantial PRA ac-
tivity reduction, our findings identified many pretransplant
patient characteristics and operative variables as predictorsrdiovascular Surgery c Volume 145, Number 2 561
FIGURE 3. Propensity scores for substantial reduction in PRA activity. This propensity score is the probability, computed from baseline variables, that any
patient would have a substantial reduction (>20%) in PRA activity. A, Propensity scores for all patients who had a trivial reduction (light gray bars) or
a substantial reduction (dark gray bars) in PRA activity. B, Propensity score–matched patients (subset of patients from 3A matched by our propensity-
matching algorithm) who achieved a trivial (light gray bars) or substantial (dark gray bars) reduction in PRA activity. PRA, Panel reactive antibody.
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American race, college education, private insurance, diag-
nosis of idiopathic dilated cardiomyopathy, diagnosis of
congenital heart disease, undergoing redo heart transplanta-
tion, year of transplant, BMI 35 kg/m2 or greater, ventilator
dependence, ECMO support, creatinine clearance less than
50 mL/min, dialysis requirement, diabetes, serum bilirubin
level 2 mg/dL or greater, organ ischemic time (hours), donor
age, and a gender match between organ and recipient562 The Journal of Thoracic and Cardiovascular Surg(Table 2). Many of the variables found in this study to
independently predict graft survival have been implicated
as predictors of post-transplant survival.22,23
Unadjusted and Adjusted Post-Transplant Survival
Our unadjusted Kaplan–Meier survival curves in sensi-
tized and nonsensitized patients suggest that sensitized
patients achieving a significant reduction in PRA activity
have a survival that approaches (but is not equal to) thatery c February 2013
FIGURE 4. Kaplan–Meier estimate of graft survival after heart transplant
in a propensity-matched cohort of patients with a peak PRA activity of
20% or more, stratified by whether a trivial or substantial reduction in
PRA activity was achieved. PRA, Panel reactive antibody.
Schaffer et al Cardiothoracic Transplantationof nonsensitized (peak PRA ¼ 0%) patients (Figure 2).
However, our unadjusted analysis of graft survival has lim-
ited implications given the significant differences among
groups in several of the preoperative and operative charac-
teristics (Table 1). We used propensity matching in an effort
to account for selection bias, and the effectiveness of our 1:1
matching algorithm is supported by the fact that the
matched groups did not significantly differ with regard to
any of the matched variables (Table 1). Of note, the Ka-
plan–Meier survival curves of the propensity-matched
groups (sensitized patients who did and did not significantly
reduce PRA activity) were similar to our unadjusted com-
parison; there were only slight differences in median and
10-year survivals (Figure 4). The results of this
propensity-matched analysis are confirmed by the main
finding of our Cox proportional hazards analysis: A sub-
stantial PRA reduction improves graft survival indepen-
dently of other patient, donor, or operative variables.Early and Late Graft Survival
Our analysis of early and late outcomes (Table 3) shows
that the primary effect of a preoperative PRA reduction in
sensitized patients lies in early (particularly 30-day)TABLE 3. Incidence of death or graft failure at various time intervals afte
Time since
transplant
Unadjusted analysis, stratified by peak and most recent P
Peak PRA ¼ 0%,
no reduction in
PRA (n ¼ 18,163)
Peak PRA  20%,
trivial reduction in
PRA (<5%) (n ¼ 1016)
Peak PRA 
substantial redu
PRA (20%) (n
No. (%) EPY No. (%) EPY No. (%)
0-30 d 1136 (6.3) 0.80 133 (13.1) 1.77 109 (8.8)
31-90 d 543 (3.2) 0.20 47 (5.4) 0.34 45 (4.0)
91-180 d 354 (2.2) 0.09 25 (3.0) 0.12 27 (2.5)
181-365 d 481 (3.0) 0.06 32 (3.9) 0.08 49 (4.6)
>1 y 7563 (49.0) 0.06 414 (53.7) 0.07 481 (47.9)
PRA, Panel reactive antibody; EPY, events per patient year after heart transplant. *P valu
comparison between 2 groups by the log-rank test.
The Journal of Thoracic and Caoutcomes and has a decreasing effect on late outcomes.
We suspect that late graft survival is more dependent on
the long-term assessment of immunogenicity and the titra-
tion of an appropriate immunosuppressive regimen.Study Limitations
Our study is limited by its retrospective nature, its sus-
ceptibility to hidden bias, and the amount of incomplete
data in the UNOS database. We attempted to address these
limitations by using multiple imputation to account for
missing variables and propensity matching to account for
selection bias. Our decision to limit our analysis to a less
recent cohort of transplant recipients makes our results
less generalizable to today’s potential waitlisted patient,
for a few reasons. First, the assays used to determine PRA
activity in the cohort we studied are dated and have lower
sensitivity and specificity for graft survival than more mod-
ern techniques.24 Second, the PRA activity assessed in this
less recent cohort did not differentiate between MHC
classes, which simplified our analysis but also made it
less applicable to more recent assay results. Third, few pa-
tients in our cohort were bridged to transplant with a VAD,
whereas this practice is common in today’s waitlisted pa-
tients; this difference has significant implications regarding
PRA activity.25 Moreover, no data were available regarding
strategies used to reduce PRA activity; therefore, although
we strongly recommend PRA reduction in sensitized
patients, we are unable to recommend a particular PRA-
reduction strategy.CONCLUSIONS
Our finding that a significant PRA reduction was inde-
pendently associated with an improvement in graft survival
both by Cox proportional hazards modeling (HR, 0.88; CI,
0.80-0.96; P ¼ .006) and in our propensity-matched Ka-
plan–Meier survival analysis (17-month improvement in
graft survival, P ¼ .007, log-rank) validates current at-
tempts to reduce PRA activity in allosensitized waitlisted
patients, and it sets the stage for future analysis of ther heart transplant
RA activity Propensity-matched analysis
20%,
ction in
¼ 1244)
Peak PRA  20%,
trivial reduction in
PRA (<5%) (n ¼ 945)
Peak PRA  20%,
substantial reduction in
PRA (20%) (n ¼ 945)
EPY P* No. (%) EPY No. (%) EPY Py
1.15 <.001 122 (12.9) 1.73 88 (9.3) 1.22 .01
0.25 .001 46 (5.6) 0.35 36 (4.2) 0.26 .19
0.10 .22 24 (3.1) 0.13 21 (2.6) 0.11 .52
0.09 .005 28 (3.7) 0.08 31 (3.9) 0.08 .86
0.06 .06 392 (53.7) 0.07 372 (48.7) 0.06 .14
e is based on comparison among 3 groups by the log-rank test. yP value is based on
rdiovascular Surgery c Volume 145, Number 2 563
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Xeffects of PRA reduction in a more recent cohort of trans-
plant recipients.
Stephen N. Palmer, PhD, ELS, contributed to the editing of the
manuscript.References
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Dr Joseph C. Cleveland (Aurora, Colo). The management of
an allosensitized potential cardiac transplant recipient remains
highly anecdotal and center specific as outlined in the presentation.
In essence, each center possesses its own witch’s brew—the treat-
ment to reduce PRA levels, including plasmapheresis, intravenous
immunoglobulin, and some novel newer agents.
This analysis by Schaffer and colleagues is important and seeks
to provide guidance for managing these allosensitized patients.
The findings of the present study are novel and important. Both
the peak PRA level and the inability to reduce the PRA level by
less than 20% leads to an inferior allograft survival, at least in
this UNOS registry over a 10-year period. I applaud the authors’
use of propensity matching to try to equal as much as you can,
make the patient comorbidities as equitable as possible. I have 3
questions.
My first question pertains to the obvious choice of time periods
for analysis as you outlined. The way that we now analyze PRA in
the cell-based Luminex (Austin, Tex) technology is so different
than in the prior era of 1987-2004. I acknowledge your desire to
keep a homogeneous patient population, but why not focus on
the period of transplantation that we are now dealing with, from
2004 to 2010. What made you want to look from 1987 to 2004?
What about a patient who has a PRA of a mean fluorescent inten-
sity of 2000 units in one of these cell-based technologies: Do you
think your data really will help us deal with that type of patient?
Dr Schaffer (Stanford, Calif). To be honest, the real reason we
started this study of the ‘‘older’’ era was to simplify our analysis
and to serve as a starting point for future study. If we could prove
that a reduction in MHC class I PRA levels before transplant inde-
pendently improved long-term survival in the ‘‘older era’’ cohort,
we would have a good starting point to try and differentiate
between the different assays used in the more recent PRA era.
This study serves as our starting point. We now know that
a PRA reduction independently improves post-transplantation sur-
vival. Now we have to try and figure out how it works in the more
recent era. Factors that complicate this analysis are that more
recent technologies assess both class 1 and 2 PRA percentages.
Now we can try and assess whether a reduction in a particular
MHC class matters more, and to try to determine how the different
methods of measuring PRA level in the more recent era affects the
documented levels of PRA activity.
Dr Cleveland. Fair enough. So you report your primary end
graft is allograft survival. One of the potential risks to aggressive
desensitization protocols is the occurrence of excess mortality
after transplantation that is due to infectious causes. Was overall
patient survival between these groups analyzed? Do you have
those data?ery c February 2013
Schaffer et al Cardiothoracic TransplantationDr Schaffer. I do not have the curve to show you, but from our
experience the post-transplant graft survival and mortality curves
are similar. The study’s primary end point is a composite of all
cause mortality and graft failure, which we believe is the most
appropriate end point for this analysis.
Dr Cleveland. You do not think you saw an excess signal indi-
cating mortality from infectious causes at least as best you could?
Dr Schaffer. Our study did not specifically assess causes of
death, only time to graft failure or death.
DrCleveland. Last, as you acknowledge, there were not a lot of
VAD recipients in this cohort, but one of the principal methods
whereby patients develop elevated PRA levels are those that
require a left VAD as a bridge to transplantation. The Johns Hop-
kins group published an analysis from the same UNOS thoracic
registry. They stratified left VAD recipients with PRA of 0% versus
25% and observed no difference in rejection rates for the first year
after cardiac transplantation and no difference in overall patient
survival. Can you put your study in perspective with their data?
How do your data and analysis perhaps differ from their study
and other ways that patients might be treated differently to desen-
sitize them if they are a VAD recipient?
Dr Schaffer. I suspect the Hopkins group, when they were cre-
ating their study, probably ran into the same troubles that we did in
trying to decide how to differentiate between a peak and a most
recent PRA level when you have 2 different values for the 2 differ-
ent MHC classes. I suspect that is why they limited their analysis to
just the most recent PRA levels. As to differentiating ours, I think
our analysis gives you a good idea what to expect for the non-VAD
recipient, and theirs obviously is limited to VAD recipients. Their
study does make the important point as to how useful PRA levels
are in the population with VADs. We hope to assess this in our
future work assessing the more recent era.
Dr Cleveland. One last minor follow-up question in terms of
the Kaplan–Meier curves. It looks like the initial first year is really
where this difference is. Are those slopes truly similar or is there
a late risk that these patients might incur by having elevated PRA?The Journal of Thoracic and CaDr Schaffer. In our analysis there is a statistically significant
difference, but it is tiny. I forget the event rate per se, but it is so
small as to not be clinically relevant. All of that risk really comes
in the first year and most in the first 6 months.
Dr Cleveland. Nice presentation.
Dr Timothy Icenogle (Spokane, Wash). I rise to translate for
the audience what I think is an enormous contribution to medical
science. What these therapies are aimed at are basically deleting
immunologic memory, that is, to delete the memory cells of a pre-
vious exposure to somebody else’s tissues. The new studies that
you described are highly sensitive and specific. What you have
shown is that by deleting immunologic memory or at least a por-
tion of immunologic memory, there has been a reduction in bad
outcomes in transplantation. This translates well beyond the
world of transplantation to the world of autoimmune diseases,
including type 1 diabetes, amyotrophic lateral sclerosis, multiple
sclerosis, and traumatic chronic encephalopathy. If we are able to
delete immunologic memory, and in the world of transplantation
led by young surgeons such as yourself, we can now explore
ways to delete immunologic memory, this will have huge impli-
cations for the rest of medicine. In your evaluation of all of these
therapies, there has been considerable improvement. In your
studies, were you able to find any therapies that were perhaps
more successful than other therapies in deleting immunologic
memory?
Dr Schaffer. You have identified the biggest problem with our
study. I must not have made it clear during my talk, but the huge
limitation of the UNOS database is that we do not have the under-
lying treatment as to what these patients received. We just know
that they had a high PRA level and that it was substantially reduced
at the time of transplant. I wish I had those data (treatment type).
To my knowledge, those data are not prospectively collected in the
UNOS database. That is obviously the key to this, and we do not
have that right now, but in newer data sets in the more recent era
we do have some of those data. We will be trying to assess that
in future studies.rdiovascular Surgery c Volume 145, Number 2 565
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